Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Long-Term Risks and Management of Permanent Fillers: Inflammatory Nodules, Hypercalcemia, Renal Failure, and New Treatments

Description

The speaker, a Brazilian dermatologist, reviewed long-term complications of permanent fillers, especially PMMA, emphasizing that most adverse events are immune-mediated and can present years after injection. The main problems described were chronic inflammatory nodules, edema, infection, ASIA syndrome, HIV-related inflammatory reactions, and, importantly, hypercalcemia with renal failure after large-volume gluteal injections. She explained that granulomatous inflammation may increase 1-alpha hydroxylase activity, raising calcitriol and calcium levels, which can lead to kidney stones and renal dysfunction, and noted that early markers include elevated calcium and calcitriol with suppressed PTH. Case series and individual cases showed that large PMMA volumes, especially in the buttocks, were associated with these systemic complications, and surgical removal sometimes improved calcium and renal function, supporting the causal link. She also discussed newer medical treatments, highlighting methotrexate and especially JAK inhibitors such as tofacitinib and abrocitinib as promising options for inflammatory filler nodules and sarcoid-like reactions, while stressing the need to exclude infection first and to be cautious with methotrexate in women of childbearing age. Overall, she argued for stricter regulation of permanent filler use, avoidance of large volumes, preference for reversible fillers, and a treatment approach that combines careful screening, immunomodulatory therapy, and surgery only for resistant or severe cases.

View more

Conclusions

The main long-term complications of permanent fillers are chronic inflammatory nodules, edema, infection, and in severe high-volume cases hypercalcemia with renal failure.
These adverse events appear to be driven by immune-mediated foreign-body inflammation, granuloma formation, fibrosis, and genetic susceptibility rather than by simple mechanical injury alone.
Large-volume PMMA injections in the gluteal region are especially associated with delayed hypercalcemia, kidney stones, renal insufficiency, and chronic kidney failure.
ASIA syndrome and HIV-related IRIS can occur as less common immune complications, particularly when host predisposition or immune reconstitution is present.
Because permanent filler reactions share a cytokine-driven pathway, especially involving interferon and other inflammatory mediators, immunologic treatment is more rational than purely procedural management.
Methotrexate and JAK inhibitors are presented as effective newer treatments for many inflammatory filler complications, often outperforming corticosteroids.
Tofacitinib and related JAK inhibitors may improve PMMA granulomas and other filler reactions by suppressing the cytokine network that sustains granulomatous inflammation.
Surgery still has a role, especially for immunosuppressant-resistant cases, ASIA syndrome, or very large filler volumes, and it may rapidly improve calcium and renal abnormalities.
The improvement in calcium, creatinine, PTH, and calcitriol after PMMA removal supports a causal link between permanent fillers and systemic metabolic-renal complications.
Prevention should emphasize reversible fillers, avoidance of large-volume PMMA, strict regulation, and screening of high-risk patients before treatment.

Janhez M. et al., Aesthetic Plastic Surgery, 2025.
Sampaio MMA et al. review of polymethyl methacrylate complication reports.
Cohen Tervaert and Montealegre.
Landau M. et al. on oral methotrexate for delayed-onset inflammatory reactions to dermal fillers.#10.1093/asjof/ojae011
Iahnez M. et al. on PMMA granulomas treated with tofacitinib.
Ianhez M, Miot HA, et al. 2024 Indian Journal of Dermatology article on sarcoidosis and PMMA granulomas treated with tofacitinib.
2025 case report on successful treatment of cutaneous foreign body granuloma with JAK inhibitor abrocitinib and prednisone.#10.2147/ccid.s522469